Daily CSR https://www.dailycsr.com/ 2026-07-30T11:05:18+02:00 Webzine Maker https://www.dailycsr.com/favicon.ico AsymBio Expands Biologics CDMO with New Shanghai R&D Center 2026-07-27T15:54:00+02:00 https://www.dailycsr.com/AsymBio-Expands-Biologics-CDMO-with-New-Shanghai-R-D-Center_a5993.html https://www.dailycsr.com/photo/art/imagette/97489427-67887309.jpg 2026-07-27T15:52:00+02:00 Debashish Mukherjee AsymBio Expands Biologics CDMO with New Shanghai R&D Center

AsymBio, the biologics-focused Contract Development and Manufacturing Organization (CDMO) under the Asymchem Group (stock codes: 002821.SZ / 6821.HK), has announced the groundbreaking of a new research and development facility at its Fengxian campus in Shanghai. This expansion represents a major milestone in enhancing the company's biologics CDMO capabilities while further establishing the Fengxian site as a key center for research, development, and manufacturing.

Construction commenced in May 2026, with completion and operational launch planned for the second half of 2027. The eight-story building will occupy approximately 2,500 square meters of land and offer nearly 20,000 square meters of total floor space. Designed in accordance with green and low-carbon building principles, the facility will house capabilities for cell line development, upstream and downstream process development, conjugation process development, drug product development, and advanced analytical services.

Situated alongside AsymBio's existing clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs) at the Fengxian campus, the new R&D center will serve as a dedicated innovation hub. Its close integration with manufacturing operations is expected to improve technology transfer, facilitate efficient scale-up, and accelerate the transition from development to commercial production.

The facility will also host the AccPCC (Accelerated PCC Platform), an integrated research and development framework designed to reduce the time required to advance drug candidates from lead identification to preclinical candidate (PCC) selection. Leveraging AI-enabled, end-to-end workflows, the platform brings together early-stage research, Chemistry, Manufacturing and Controls (CMC), nonclinical evaluation, and early clinical translation. It offers comprehensive support in lead optimization, developability assessment, and customized early-stage CMC strategies for biotechnology companies worldwide.

Commenting on the initiative, AsymBio CEO Rui Yang emphasized that successful biologics development depends on early collaboration, integrated scientific and CMC decision-making, and consideration of manufacturability from the beginning of a project. By utilizing the combined R&D expertise available across the Asymchem Group, the AccPCC platform aims to enhance development efficiency, accelerate preclinical candidate selection, and shorten the journey from scientific discovery to clinical application.

The new Fengxian R&D building is expected to strengthen collaboration between research, process scale-up, and manufacturing, enabling clients to minimize development bottlenecks and manage complex biologics programs with greater efficiency and confidence.


]]> Pfizer’s ACMF Wins The ‘2020 Facility of the Year Award’ 2020-04-30T19:15:00+02:00 https://www.dailycsr.com/Pfizer-s-ACMF-Wins-The-2020-Facility-of-the-Year-Award_a1747.html https://www.dailycsr.com/photo/art/imagette/45542375-36733527.jpg 2020-04-30T19:10:00+02:00 Lorene Stevens Pfizer’s ACMF Wins The ‘2020 Facility of the Year Award’
Dailycsr.com – 30 April 2020 – One of “state-of-the-art facility” allowed Pfizer Inc. to make a significant expansion in its “clinical manufacturing” on a global scale besides speeding up the delivery of critical therapies to patients, whereby the said facility received the “2020 Facility of the Year Award for Facility Integration” which was awarded by the “International Society for Pharmaceutical Engineering”.
 
On 8th of April, the announcement was made by the ISPE honouring the “Andover Clinical Manufacturing Facility”, in short the ACMF, of Pfizer. The said facility was designed as well as engineered by CRB, which was chosen by Pfizer for shaping the facility so that the latter could move its “BioTherapeutics Pharmaceutical Sciences group” to the new ACMF located at Andover, Massachusetts.
 
With the expanding area Pfizer can better manage its “rising portfolio of GMP-compliant, clinical bulk drug substances”, as it will have a capacity for twenty one annual campaigns with three being “pivotal trial”. The ACMF design of CRB features “single-use bioreactors” as well as “disposable process technologies” while maintaining “traditional fixed stainless-steel equipment” which offers low-cost and flexible options for “clinical manufacturing”. While CRB’s press release further informed that:
“A set of five cell culture and microbial manufacturing suites are flexibly configured to accommodate Pfizer’s future process developments”.
 
Moreover, in the words of the Senior Project Manager at CRB, Jeff Matis:
“By creating new connections between Pfizer’s clinical manufacturing and commercial manufacturing capabilities, the ACMF marks a physical, operational, and intellectual integration that better informs the biologic process, bolsters quality and improves patient access to potentially life-changing treatments. We are proud to join Pfizer in this important work, and we congratulate them for the foresight and focus on facility integration that earned them this great honor.”
 
 
 
References:
3blmedia.com

]]>